MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second… Dec 16, 2021
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s… Dec 16, 2021
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application Dec 15, 2021
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine)… Dec 15, 2021
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Dec 15, 2021
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share… Dec 15, 2021
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent… Dec 14, 2021
